These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 16300168)
61. Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. Lamson M; Phillips G; Shen J; Lukacsko P; Friedhoff L; Niecestro RM Biopharm Drug Dispos; 2002 May; 23(4):143-9. PubMed ID: 12015788 [TBL] [Abstract][Full Text] [Related]
62. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Sealey JE; Laragh JH Am J Hypertens; 2007 May; 20(5):587-97. PubMed ID: 17485026 [TBL] [Abstract][Full Text] [Related]
63. Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. Itthipanichpong C; Chompootaweep S; Wittayalertpanya S; Kemsri W; Thaworn N; Lilitkarntrakul P; Parikamsil S J Med Assoc Thai; 2005 May; 88(5):632-8. PubMed ID: 16149679 [TBL] [Abstract][Full Text] [Related]
64. Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: a comparative study. Wójcicki J; Wojciechowski G; Wójcicki M; Kostyrka R; Sterna R; Gawronska-Szklarz B; Pawlik A; Drozdzik M; Kozlowski K Eur J Clin Pharmacol; 2000 Apr; 56(1):75-9. PubMed ID: 10853882 [TBL] [Abstract][Full Text] [Related]
65. Exenatide effects on statin pharmacokinetics and lipid response. Kothare PA; Linnebjerg H; Skrivanek Z; Reddy S; Mace K; Pena A; Han J; Fineman M; Mitchell M Int J Clin Pharmacol Ther; 2007 Feb; 45(2):114-20. PubMed ID: 17323791 [TBL] [Abstract][Full Text] [Related]
66. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456 [TBL] [Abstract][Full Text] [Related]
67. Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. Cooper DL; Wood RC; Wyatt JE; Harirforoosh S Eur J Pharm Sci; 2014 Mar; 53():28-34. PubMed ID: 24342124 [TBL] [Abstract][Full Text] [Related]
68. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS). Volman S; Benitez FN; Cedenio H; Giorgi M; Jaramillo N; Molina N; Zilberman J Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):189-96. PubMed ID: 23723254 [TBL] [Abstract][Full Text] [Related]
69. Plasma pharmacokinetics and synovial fluid concentrations after oral administration of single and multiple doses of celecoxib in greyhounds. Hunter RP; Radlinsky M; Koch DE; Corse M; Pellerin MA; Halstead J Am J Vet Res; 2005 Aug; 66(8):1441-5. PubMed ID: 16173491 [TBL] [Abstract][Full Text] [Related]
70. Interactions of aliskiren, a direct renin inhibitor, with antiepileptic drugs in the test of maximal electroshock in mice. Łukawski K; Raszewski G; Czuczwar SJ Eur J Pharmacol; 2018 Jan; 819():108-113. PubMed ID: 29191768 [TBL] [Abstract][Full Text] [Related]
71. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Kivistö KT; Kantola T; Neuvonen PJ Br J Clin Pharmacol; 1998 Jul; 46(1):49-53. PubMed ID: 9690949 [TBL] [Abstract][Full Text] [Related]
72. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B; Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265 [TBL] [Abstract][Full Text] [Related]
73. Aliskiren, the future of renin-angiotensin system blockade? Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914 [TBL] [Abstract][Full Text] [Related]
74. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Tiseo PJ; Perdomo CA; Friedhoff LT Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):25-9. PubMed ID: 9839762 [TBL] [Abstract][Full Text] [Related]
75. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J; Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266 [TBL] [Abstract][Full Text] [Related]
76. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832 [TBL] [Abstract][Full Text] [Related]
77. Aliskiren toxicity in juvenile rats is determined by ontogenic regulation of intestinal P-glycoprotein expression. Hoffmann P; Beckman D; McLean LA; Yan JH Toxicol Appl Pharmacol; 2014 Feb; 275(1):36-43. PubMed ID: 24388840 [TBL] [Abstract][Full Text] [Related]
78. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Davies NM; McLachlan AJ; Day RO; Williams KM Clin Pharmacokinet; 2000 Mar; 38(3):225-42. PubMed ID: 10749518 [TBL] [Abstract][Full Text] [Related]
79. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696 [TBL] [Abstract][Full Text] [Related]
80. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. Sepehrdad R; Frishman WH; Stier CT; Sica DA Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]